B
BioNTech
Develops personalized immunotherapies with a focus on cancer medicine
At a glance
- Founded
- 2008
- Headquarters
- Mainz, Germany
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning BioNTech.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- AVATHOS Venture
- MCMIG Capital
- SHSanto Holding
Series A6 investors entered at this stage
- INInvus
- RGRedmile Group
Janus Henderson Investors- ELEli Lilly
- JHJanus Henderson
Fidelity Investments
Series B and later8 investors entered at this stage
- PMPlatinum Asset Management
- JMJohannes Gutenberg University Mainz
- JCJebsen Capital
- MIMirae Asset Venture Investment
Temasek- SASanofi
- GEGenentech
- BABayer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
583 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where BioNTech was the backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
13 deals across BioNTech's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where BioNTech deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
BioNTech's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioNTech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioNTech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.